May 25, 2021: A new case study is presented, in which the use of spheroids for the determination of drug sensitivity is highlighted. The figure shows dose-response curves of the KRAS G12C inhibitor sotorasib (AMG-510) in viability assays with KRAS wild-type and KRAS G12C mutant cell lines in 2D and 3D culture (top) and spheroid morphology of the cell lines (bottom).
Altered drug response in 3D spheroids
Spheroid cultures are an attractive model for anticancer drug screening in a complex cellular environment. A new case study is now available on our website, in which the use of spheroids for the determination of drug sensitivity is highlighted. The small molecule inhibitor sotorasib (AMG-510), which selectively and irreversibly targets the KRAS G12C mutant, is used as a model drug to compare drug response in 3D spheroids and 2D monolayer cultures of KRAS wild-type and KRAS G12C mutant cell lines. Highlights of this case study are the direct comparison of spheroid and monolayer cultures under the same conditions, and the evaluation of drug sensitivity based on both spheroid morphology and cell viability.
NTRC is a precision medicine company dedicated to discovering new anti cancer drug candidates. We help you to find a mechanistic hypothesis before entering the clinic. We can study a wide range of cancer cells, primary patient material and immune cells in vitro, in isolation and in coculture, after exposure to monotherapy and combination therapy. In addition, we perform in-depth mechanistic analyses in cells and by biophysical methods, such as Biacore and LC-MS/MS. Keywords are: Quality. Flexibility. Short Turnaround Time.